Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02163967 · ClinicalTrials.gov registry record · Phase 4
Effect of CES on Parasympathetic Tone
A Phase 4 study of Autonomic Nervous System Imbalance, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT02163967: Completed Phase 4 study of Autonomic Nervous System Imbalance, sponsored by Weill Medical College of Cornell University.
NCT02163967 is a Phase 4 study of Autonomic Nervous System Imbalance that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 21 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02163967, a Phase 4 study of Autonomic Nervous System Imbalance, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The hypothesis is that CES stimulation will dose dependently increase parasympathetic tone. Healthy subjects will have three 20 minute sessions of CES stimulation, at three different intensities of stimulation, with each session occurring on a separate day. Effect on parasympathetic tone will determined by measuring high frequency heart rate variability before, during and after the stimulation. The Fisher Wallace Stimulator (FW100) which delivers a low dose alternating current a varying frequencies will be used for the stimulation.
Primary Outcome
High frequency heart rate variability (HRV) will be calculated over successive 5 minute intervals from continuous ECG recordings and reported on a log scale with a minimum of 0 and a maximum of 10. Higher scores represent more heart rate variability.
Conditions Studied
Interventions
- DEVICE Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100)
Study Locations (1)
New York
- Weill Cornell Medical College - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2013-01-11 |
| Est. Completion | 2013-03-15 |
| Phase | Phase 4 |
What the finished NCT02163967 record still lists
NCT02163967 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Autonomic Nervous System Imbalance appearing as the primary indexed condition, and to 1 intervention - of which Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100) is the first listed.
NCT02163967 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02163967 about?
NCT02163967 is a clinical study titled "Effect of CES on Parasympathetic Tone". The hypothesis is that CES stimulation will dose dependently increase parasympathetic tone. Healthy subjects will have three 20 minute sessions of CES stimulation, at three different intensities of stimulation, with each session occurring on a separate day. Effect on parasympathetic tone will determ...
What is the current status of trial NCT02163967?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2013-01-11. Estimated completion is 2013-03-15.
What conditions does trial NCT02163967 study?
This clinical trial studies the following conditions: Autonomic Nervous System Imbalance.
What interventions are being tested in trial NCT02163967?
The interventions under investigation include: Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100) (DEVICE).
Who is sponsoring clinical trial NCT02163967?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02163967 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autonomic Nervous System Imbalance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02163967's enrollment target sits among peer trials
21 1742nd of 2000 higher than 249 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI